Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

GENFIT reported strong first-half 2026 financial results with €113.8 million in cash, driven by tripling royalty revenues from Ipsen's Iqirvo® (€21.1 million) and a €17 million milestone payment. The company is advancing three Phase 2 clinical trials including nangibotide and nitazoxanide for ACLF, while its NIS™ diagnostic technology achieved Medicare coverage for NASHnext®. Ipsen doubled Iqirvo's peak sales target to €1 billion for PBC, and IQVIA estimates NIS™-based products could exceed $1.5 billion in U.S. peak sales by 2033.

09/28/2026, 1:51 PM • GlobeNewswire

Ipsen nomme Mariette Finet administratrice au sein de son Conseil d’administration

Ipsen announces the appointment of Mariette Finet as a board member, effective immediately, replacing Michèle Ollier who resigned on August 1, 2026. Finet brings over 35 years of experience in healthcare, pharmaceuticals, and life sciences. She will also serve on the Product Portfolio Committee. The board remains composed of 14 members with balanced gender representation (7 women, 7 men). Her appointment is subject to shareholder ratification at the next general assembly.

09/18/2026, 3:26 AM • GlobeNewswire

Ipsen appoints Mariette Finet to its Board of Directors

Ipsen announced the appointment of Mariette Finet as a Director to its Board of Directors, effective immediately, succeeding Michèle Ollier who resigned on August 1, 2026. Finet brings over 35 years of healthcare and pharmaceutical experience. She will also join the Board Portfolio Committee. The appointment maintains the board's composition at 14 directors with balanced gender representation (7 women, 7 men) and will be submitted for ratification at the next Annual Shareholders' Meeting.

09/18/2026, 3:26 AM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026

IPSEN conducted share repurchases during the week of September 7-11, 2026, acquiring a total of 35,759 shares at a weighted average price of €158.52 across multiple markets including XETRA, Euronext Paris, and TQEX. No transactions were recorded on September 10, 2026.

09/14/2026, 12:00 PM • GlobeNewswire

GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been admitted to the Euronext Paris CAC Mid 60 and SBF 120 indices effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its profile among institutional investors.

09/11/2026, 1:30 AM • GlobeNewswire

GENFIT va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris

GENFIT, a biopharmaceutical company focused on rare liver diseases, has been included in the Euronext Paris indices CAC Mid 60 and SBF 120, effective September 18, 2026. The inclusion reflects the company's increased market capitalization, liquidity, and visibility, and is expected to enhance its reputation among institutional investors. The company continues to develop therapeutic and diagnostic solutions, including the FDA-approved Iqirvo® for primary biliary cholangitis.

09/11/2026, 1:30 AM • GlobeNewswire

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 35 - 2026

Ipsen has completed its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. This acquisition strengthens Ipsen's late-stage oncology pipeline, representing a strategic expansion of its oncology portfolio.

08/31/2026, 12:00 PM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026

Ipsen has completed its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. This acquisition strengthens Ipsen's late-stage oncology pipeline, representing a strategic expansion of its oncology portfolio.

08/31/2026, 12:00 PM • GlobeNewswire

Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The announcement also includes a corrective statement regarding voting rights disclosure as of June 30, 2026.

07/22/2026, 12:00 PM • GlobeNewswire

Ipsen - Déclaration rectificative corrigeant la déclaration mensuelle du nombre total d'actions et de droits de vote au 30 juin 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The company also published a corrective declaration regarding voting rights and share capital figures as of June 30, 2026.

07/22/2026, 12:00 PM • GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026

Ipsen conducted share repurchases totaling 28,541 shares between July 6-10, 2026, at an average price of €166.05. The company announced that Dysport (botulinum toxin) achieved positive Phase III results in both episodic and chronic migraine trials, becoming the first botulinum toxin to meet primary endpoints in both indications.

07/15/2026, 12:00 PM • GlobeNewswire

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine xx - 2025

Ipsen conducted share buybacks between July 6-10, 2026, purchasing 28,541 shares at an average price of €166.05. The company announced that Dysport (botulinum toxin) achieved positive Phase III results in both episodic and chronic migraine trials, becoming the first botulinum toxin to meet primary endpoints in both indications.

07/15/2026, 12:00 PM • GlobeNewswire

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GENFIT announced positive Phase 1b results for GNS561, an investigational drug targeting autophagy, in combination with a MEK inhibitor for treating advanced KRAS-mutated cholangiocarcinoma. The study of 19 patients showed a favorable safety profile with no dose-limiting toxicities and early signs of antitumor activity, with approximately half achieving stable disease. Phase 2 initiation is planned for the second half of 2026.

06/23/2026, 12:00 PM • GlobeNewswire

GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités

GENFIT reported positive Phase 1b results for GNS561 combined with a MEK inhibitor in heavily pretreated cholangiocarcinoma patients with KRAS mutations. The drug demonstrated favorable safety and tolerability profiles with no dose-limiting toxicities, along with early signs of antitumor activity. Approximately half of the 19 patients achieved stable disease at Week 6, with one patient maintaining this status through Week 30. The company plans to extend Phase 1b with additional cohorts at higher doses and proceed to Phase 2 launch in H2 2026.

06/23/2026, 12:00 PM • GlobeNewswire